ReviewJournal of mammary gland biology and neoplasia2003
Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways.
Review in Journal of mammary gland biology and neoplasia, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Prognostic role of EGR1 in breast cancer: a systematic review.BMB reports · 2021Pooled it
- Association of ApaI and TaqI polymorphisms in VDR Gene with Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Topological alternate centrality measure capturing drug targets in the network of MAPK pathways.IET systems biology · 2018Article
- Canine mammary tumors as a model for human disease.Oncology letters · 2018Review
- Deciphering the roles of lncRNAs in breast development and disease.Oncotarget · 2018Review
- Association between vitamin D receptor gene polymorphisms and breast cancer in a Chinese population.International journal of clinical and experimental medicine · 2015Article
- Pubertal bisphenol A exposure alters murine mammary stem cell function leading to early neoplasia in regenerated glands.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventive agents.Journal of medicinal chemistry · 2012Article
- The role of master regulators in the metabolic/transcriptional coupling in breast carcinomas.PloS one · 2012Article
- Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy.The American journal of pathology · 2011Article
- Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2009Article
- Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.Cancer prevention research (Philadelphia, Pa.) · 2009Article
- Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity.Cancer prevention research (Philadelphia, Pa.) · 2008Article
- The relevance of mouse models to understanding the development and progression of human breast cancer.Journal of mammary gland biology and neoplasia · 2008Review
- A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment.Molecular biology reports · 2008Article
- The low-toxicity 9-cis UAB30 novel retinoid down-regulates the DNA methyltransferases and has anti-telomerase activity in human breast cancer cells.International journal of oncology · 2007Article
- Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer.British journal of cancer · 2005Article
- Is iodine a gatekeeper of the integrity of the mammary gland?Journal of mammary gland biology and neoplasia · 2005Review
- Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells.Neoplasia (New York, N.Y.) · 2005Article
- Gene and protein expressions induced by 17beta-estradiol and parathion in cultured breast epithelial cells.Molecular medicine (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transformation of breast cells occurs through loss or mutation of tumor suppressor genes, or activation or amplification of oncogenes, leading to deregulation of signal transduction pathways, abnormal amplification of growth signals, and aberrant expression of genes that ultimately transform the cells into invasive cancer. The goal of cancer preventive therapy, or "chemoprevention," is to eliminate premalignant cells or to block the progression of normal cells into cancer. Multiple alterations in signal pathways and transcription factors are observed in mammary gland tumorigenesis. In particular, estrogen receptor (ER) deregulation plays a critical role in breast cancer development and progress, and targeting ER with selective ER modulators (SERMs) has achieved significant reduction of breast cancer incidence in women at high risk for breast cancer. However, not all breast cancer is prevented by SERMs, because 30-40% of the tumors are ER-negative. Other receptors for retinoids, vitamin D analogs and peroxisome proliferator-activiator, along with transcription factors such as AP-1, NF-kappaB, and STATs (signal transducers and activators of transcription) affect breast tumorigenesis. This is also true for the signal transduction pathways, for example cyclooxygenase 2 (Cox-2), HER2/neu, mitogen-activated protein kinase (MAPK), and PI3K/Akt. Therefore, proteins in pathways that are altered during the process of mammary tumorigenesis may be promising targets of future chemopreventive drugs. Many newly-developed synthetic or natural compounds/agents are now under testing in preclinical studies and clinical trials. Receptor selective retinoids, receptor tyrosine kinase inhibitors (TKIs), SERMs, Cox-2 inhibitors, and others are some of the promising novel agents for the prevention of breast cancer. The chemopreventive activity of these agents and other novel signal transduction inhibitors are discussed in this chapter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.